ActX Announces Issuance of U.S. Patent for Real-Time Genomic Decision Support

Share Article

The patent covers methods and systems for organizing, storing, searching, aggregating, and distributing large quantities of biological information obtained for individual patients.

As a physician, I realized that the current method of ‘trial and error’ for prescribing medications can be substantially improved using genomics

ActX’s genetic clinical decision support service, also known as GenoACTTM, helps physicians provide better care using the patients’ genetic data. Today, ActX announced that the U.S. Patent and Trademark Office has issued Patent No. 10,586,612. It covers methods and systems for organizing, storing, searching, aggregating, and distributing large amounts of biological information obtained for individual patients. With ActX, once patients are genotyped or sequenced, their data is stored in the cloud and referenced in real time. This provides physicians with real time decision support as they use their Electronic Medical Record. For example, if a physician writes a prescription for a medication that may not be effective, then based on the patient’s genetics, ActX will provide an alert in their normal workflow. The alert has minimal latency, succinctly informs the physician, and provides suggestions for more effective treatment.

The patent covers the use of electronic biological information, stored and distributed through a cloud-like information storage facility to patients, clinicians, and electronic health record-based applications. The ability to provide patients and their physicians with actionable information quickly in real time, based on a large amount of genetic data, in normal physician workflow, is new to the healthcare industry. This was developed by ActX’s CEO, Dr. Andrew Ury, and Software Engineer Michael Arlt. The ‘612’ Patent covers 21 claims and is valid through March 3rd, 2034.

“The service we have created with ActX helps make genomics actionable, a key part of which is pharmacogenomics, in everyday medical practice,” said Dr. Andrew Ury, founder of ActX. “As a physician, I realized that the current method of ‘trial and error’ for prescribing medications can be substantially improved using genomics. Instead of trying out a medication for months to see if it works or causes serious side effects, physicians and patients can, for many medications, using genetics, know in advance whether a medication is likely to work or cause side effects. The approval of this patent allows us to continue with our mission of making real-time genomic decision support a standard in patient care.”

This newly allowed patent is owned by ActX, with the inventors being Andrew Ury and Michael Arlt. It is one of the latest U.S. patents issued in connection with precision medicine and cloud-based information storage and sharing.

About ActX

ActX is the industry leader in EHR-integrated precision medicine. Our service helps physicians make better decisions about medical treatment, using a patient’s genetic information to guide therapy. The ActX Genomic Service offers proven, tightly integrated, real-time genomic decision support for medication orders and actionable genomic risks, a built in patient Genomic Profile, and the ability to fully customize content.

As medications are ordered, and before the prescription is finalized, medications are checked against the patient’s genetics for efficacy, adverse reactions, and dosing. Extensive evidence based and actionable content is provided as default, customizable content, covering hundreds of genes. You can easily suppress any content or interactions, or add or modify content. The ActX Genomic Service is live at numerous U.S. health systems. For more information, visit http://www.actx.com, email info@actx.com or call 888-998-2289.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ellie Newby
ActX
+1 (888) 998-2289 Ext: 101
Email >
Visit website